Search

Your search keyword '"Lerede, Teresa"' showing total 33 results
Start Over Author "Lerede, Teresa"
33 results on '"Lerede, Teresa"'

1. More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study

Author

Testa, Sophie, Dellanoce, Claudia, Paoletti, Oriana, Morandini, Rossella, Tala, Maurizio, Ciampa, Antonio, Gaeta, Martina, Chiarugi, Paolo, Casini, Monica, Guerri, Valentina, Santoro, Rita Carlotta, Iannaccaro, Piergiorgio, Iannone, Angela Maria, Campagna, Maddalena, De Candia, Erica, Alberelli, Maria Adele, Basso, Maria, De Cristofaro, Raimondo, Di Gennaro, Leonardo, Ferretti, Antonietta, Sorrentino, Silvia, Pignatelli, Pasquale, Menichelli, Danilo, Pastori, Daniele, Saliola, Mirella, Faioni, Elena Maria, Avarello, Ilaria, Razzari, Cristina, Chistolini, Antonio, Aprile, Simona Michela, Santoro, Cristina, Serrao, Alessandra, Esteban, Maria del Pilar, Ricca, Sergio, Marietta, Marco, Arletti, Laura, Coluccio, Valeria, Debbia, Giulia, Grisolia, Deborah, Serra, Domizio, Orselli, Alberto, Pescarollo, Alessandra, Verna, Sandra, Di Gregorio, Patrizia, Cassetti, Giuseppina, Molteni, Mauro, Monelli, Mauro, Paparo, Carmelo, Resani, Guido, Di Gregorio, Nicoletta, Grassi, Davide, Lodigiani, Corrado, Banfi, Elena, Ferrazzi, Paola, Librè, Luca, Pacetti, Veronica, Sacco, Clara, Bucciarelli, Paolo, Martinelli, Ida, Abbattista, Maria, Artoni, Andrea, Capecchi, Marco, Gianniello, Francesca, Scimeca, Barbara, Turrini, Anna, Moretta, Francesca, Parise, Giorgio, Zeccardo, Ciro, Fregoni, Vittorio, Balboni, Massimo, Leggio, Federico, Poli, Daniela, Ria, Luigi, Spagnolo, Marina, Dirienzo, Giovanni, Dirienzo, Lavinia, Fuzio, Diana, Donadini, Marco Paolo, Squizzato, Alessandro, Ageno, Walter, Colombo, Giovanna, Galliazzo, Silvia, Gallo, Andrea, Tamborini Permunian, Eleonora, Virano, Alexandra, Falanga, Anna, Barcella, Luca, Gamba, Sara, Lerede, Teresa, Maggioni, Anna, Russo, Laura, Schieppati, Francesca, Zunino, Federica, Barillari, Giovanni, Bertone, Antonella, Poz, Alessandra, Venturelli, Ugo, Serricchio, Giuseppina, Brevi, Francesca, Palareti, Gualtiero, Legnani, Cristina, Cini, Michela, Antonucci, Emilia, Tripodi, Armando, and Tosetto, Alberto

Published
2024
Full Text
View/download PDF

2. Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study

Author

Testa, Sophie, Dellanoce, Claudia, Paoletti, Oriana, Morandini, Rossella, Tala, Maurizio, Ciampa, Antonio, Gaeta, Martina, Chiarugi, Paolo, Casini, Monica, Guerri, Valentina, Santoro, Rita Carlotta, Iannaccaro, Piergiorgio, Iannone, Angela Maria, Campagna, Maddalena, De Candia, Erica, Alberelli, Maria Adele, Basso, Maria, De Cristofaro, Raimondo, Di Gennaro, Leonardo, Ferretti, Antonietta, Sorrentino, Silvia, Pignatelli, Pasquale, Menichelli, Danilo, Pastori, Daniele, Saliola, Mirella, Faioni, Elena Maria, Avarello, Ilaria, Razzari, Cristina, Chistolini, Antonio, Aprile, Simona Michela, Santoro, Cristina, Serrao, Alessandra, Esteban, Maria del Pilar, Ricca, Sergio, Marietta, Marco, Arletti, Laura, Coluccio, Valeria, Debbia, Giulia, Grisolia, Deborah, Serra, Domizio, Orselli, Alberto, Pescarollo, Alessandra, Verna, Sandra, Di Gregorio, Patrizia, Cassetti, Giuseppina, Molteni, Mauro, Monelli, Mauro, Paparo, Carmelo, Resani, Guido, Di Gregorio, Nicoletta, Grassi, Davide, Lodigiani, Corrado, Banfi, Elena, Ferrazzi, Paola, Librè, Luca, Pacetti, Veronica, Sacco, Clara, Bucciarelli, Paolo, Martinelli, Ida, Abbattista, Maria, Artoni, Andrea, Capecchi, Marco, Gianniello, Francesca, Scimeca, Barbara, Turrini, Anna, Moretta, Francesca, Parise, Giorgio, Zeccardo, Ciro, Fregoni, Vittorio, Balboni, Massimo, Leggio, Federico, Poli, Daniela, Ria, Luigi, Spagnolo, Marina, Dirienzo, Giovanni, Dirienzo, Lavinia, Fuzio, Diana, Donadini, Marco Paolo, Squizzato, Alessandro, Ageno, Walter, Colombo, Giovanna, Galliazzo, Silvia, Gallo, Andrea, Permunian, Eleonora Tamborini, Virano, Alexandra, Falanga, Anna, Barcella, Luca, Gamba, Sara, Lerede, Teresa, Maggioni, Anna, Russo, Laura, Schieppati, Francesca, Zunino, Federica, Barillari, Giovanni, Bertone, Antonella, Poz, Alessandra, Venturelli, Ugo, Serricchio, Giuseppina, Brevi, Francesca, Palareti, Gualtiero, Legnani, Cristina, Cini, Michela, Antonucci, Emilia, Tripodi, Armando, and Tosetto, Alberto

Published
2024
Full Text
View/download PDF

3. Statins under-treatment and mortality in patients with atrial fibrillation. Insights from the nationwide START registry

Author

Testa, Sophie, Cosmi, Benilde, Guazzaloca, Giuliana, Migliaccio, Ludovica, Poli, Daniela, Marcucci, Rossella, Maggini, Niccolò, Pengo, Vittorio, Falanga, Anna, Lerede, Teresa, Ruocco, Lucia, Martini, Giuliana, Pedrini, Simona, Bertola, Federica, Masciocco, Lucilla, Saracino, Pasquale, Benvenuto, Angelo, Vasselli, Claudio, Violi, Francesco, Pignatelli, Pasquale, Pastori, Daniele, Grandone, Elvira, Colaizzo, Donatella, Marzolo, Marco, Pinelli, Mauro, Mastroiacovo, Daniela, Ageno, Walter, Colombo, Giovanna, Bucherini, Eugenio, Serra, Domizio, Toma, Andrea, Barbera, Pietro, Paparo, Carmelo, Insana, Antonio, Rupoli, Serena, Malcangi, Giuseppe, Zighetti, Maddalena Loredana, Mangione, Catello, Lione, Domenico, Casasco, Paola, Nante, Giovanni, Tosetto, Alberto, Oriana, Vincenzo, Liberato, Nicola Lucio, Menichelli, Danilo, Antonucci, Emilia, and Palareti, Gualtiero

Published
2023
Full Text
View/download PDF

4. Venous thromboembolism secondary to hospitalization for COVID-19: patient management and long-term outcomes

Author

Ageno, Walter, Girardi, Laura, Sterpone, Paola, Cosmi, Benilde, Bucherini, Eugenio, Chistolini, Antonio, Serrao, Alessandra, Di Nisio, Marcello, Potere, Nicola, Porreca, Ettore, Fregoni, Vittorio, Grandone, Elvira, Colaizzo, Donatella, Insana, Antonio, Lerede, Teresa, Falanga, Anna, Martinelli, Ida, Bucciarelli, Paolo, Abbattista, Maria, Martini, Giuliana, Masciocco, Lucilla, Mastroiacovo, Daniela, Pancani, Roberta, Carrozzi, Laura, Paparo, Carmelo, Pedrini, Simona, Pieralli, Filippo, Milia, Alessandro, Pignatelli, Pasquale, Menichelli, Danilo, Pizzini, Attilia Maria, Silingardi, Mauro, Podda, GianMarco, Birocchi, Simone, Poli, Daniela, Crudele, Felice, Lotti, Elena, Marcucci, Rossella, Preti, Paola Stefania, Sarti, Luca, Trovati, Alice, Caronna, Antonella, Famiglietti, Elena, Lami, Francesca, Nicolini, Alberto, Scaglioni, Federica, Testa, Sophie, Paoletti, Oriana, Tosetto, Alberto, Toma, Andrea, Villalta, Sabina, Visonà, Adriana, Zalunardo, Beniamino, Panzavolta, Chiara, Antonucci, Emilia, Podda, Gian Marco, and Palareti, Gualtiero

Published
2023
Full Text
View/download PDF

5. The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study

Author

Maraveyas, Anthony, Kraaijpoel, Noémie, Bozas, George, Huang, Chao, Mahé, Isabelle, Bertoletti, Laurent, Bartels‐Rutten, Annemarieke, Beyer‐Westendorf, Jan, Constans, Joel, Iosub, Diana, Couturaud, Francis, Muñoz, Andres J., Biosca, Mercedes, Lerede, Teresa, van Es, Nick, and Di Nisio, Marcello

Published
2021
Full Text
View/download PDF

6. More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study

Author

Palareti, Gualtiero, Testa, Sophie, Legnani, Cristina, Dellanoce, Claudia, Cini, Michela, Paoletti, Oriana, Ciampa, Antonio, Antonucci, Emilia, Poli, Daniela, Morandini, Rossella, Tala, Maurizio, Chiarugi, Paolo, Santoro, Rita Carlotta, Iannone, Angela Maria, De Candia, Erica, Pignatelli, Pasquale, Faioni, Elena Maria, Chistolini, Antonio, Esteban, Maria del Pilar, Marietta, Marco, Tripodi, Armando, Tosetto, Alberto, Testa, Sophie, Dellanoce, Claudia, Paoletti, Oriana, Morandini, Rossella, Tala, Maurizio, Ciampa, Antonio, Gaeta, Martina, Chiarugi, Paolo, Casini, Monica, Guerri, Valentina, Santoro, Rita Carlotta, Iannaccaro, Piergiorgio, Iannone, Angela Maria, Campagna, Maddalena, De Candia, Erica, Alberelli, Maria Adele, Basso, Maria, De Cristofaro, Raimondo, Di Gennaro, Leonardo, Ferretti, Antonietta, Sorrentino, Silvia, Pignatelli, Pasquale, Menichelli, Danilo, Pastori, Daniele, Saliola, Mirella, Faioni, Elena Maria, Avarello, Ilaria, Razzari, Cristina, Chistolini, Antonio, Aprile, Simona Michela, Santoro, Cristina, Serrao, Alessandra, Esteban, Maria del Pilar, Ricca, Sergio, Marietta, Marco, Arletti, Laura, Coluccio, Valeria, Debbia, Giulia, Grisolia, Deborah, Serra, Domizio, Orselli, Alberto, Pescarollo, Alessandra, Verna, Sandra, Di Gregorio, Patrizia, Cassetti, Giuseppina, Molteni, Mauro, Monelli, Mauro, Paparo, Carmelo, Resani, Guido, Di Gregorio, Nicoletta, Grassi, Davide, Lodigiani, Corrado, Banfi, Elena, Ferrazzi, Paola, Librè, Luca, Pacetti, Veronica, Sacco, Clara, Bucciarelli, Paolo, Martinelli, Ida, Abbattista, Maria, Artoni, Andrea, Capecchi, Marco, Gianniello, Francesca, Scimeca, Barbara, Turrini, Anna, Moretta, Francesca, Parise, Giorgio, Zeccardo, Ciro, Fregoni, Vittorio, Balboni, Massimo, Leggio, Federico, Poli, Daniela, Ria, Luigi, Spagnolo, Marina, Dirienzo, Giovanni, Dirienzo, Lavinia, Fuzio, Diana, Donadini, Marco Paolo, Squizzato, Alessandro, Ageno, Walter, Colombo, Giovanna, Galliazzo, Silvia, Gallo, Andrea, Tamborini Permunian, Eleonora, Virano, Alexandra, Falanga, Anna, Barcella, Luca, Gamba, Sara, Lerede, Teresa, Maggioni, Anna, Russo, Laura, Schieppati, Francesca, Zunino, Federica, Barillari, Giovanni, Bertone, Antonella, Poz, Alessandra, Venturelli, Ugo, Serricchio, Giuseppina, and Brevi, Francesca

Abstract

•A relationship between high baseline DOAC levels and early bleeding events in 1-year follow-up was found.•Early measurement allows to identify patients with high DOAC levels and, hopefully, to adjust treatment to reduce bleeding events.

Published
2024
Full Text
View/download PDF

7. Statins under-treatment and mortality in patients with atrial fibrillation. Insights from the nationwide START registry

Author

Menichelli, Danilo, primary, Antonucci, Emilia, additional, Pignatelli, Pasquale, additional, Violi, Francesco, additional, Palareti, Gualtiero, additional, Pastori, Daniele, additional, Testa, Sophie, additional, Cosmi, Benilde, additional, Guazzaloca, Giuliana, additional, Migliaccio, Ludovica, additional, Poli, Daniela, additional, Marcucci, Rossella, additional, Maggini, Niccolò, additional, Pengo, Vittorio, additional, Falanga, Anna, additional, Lerede, Teresa, additional, Ruocco, Lucia, additional, Martini, Giuliana, additional, Pedrini, Simona, additional, Bertola, Federica, additional, Masciocco, Lucilla, additional, Saracino, Pasquale, additional, Benvenuto, Angelo, additional, Vasselli, Claudio, additional, Grandone, Elvira, additional, Colaizzo, Donatella, additional, Marzolo, Marco, additional, Pinelli, Mauro, additional, Mastroiacovo, Daniela, additional, Ageno, Walter, additional, Colombo, Giovanna, additional, Bucherini, Eugenio, additional, Serra, Domizio, additional, Toma, Andrea, additional, Barbera, Pietro, additional, Paparo, Carmelo, additional, Insana, Antonio, additional, Rupoli, Serena, additional, Malcangi, Giuseppe, additional, Zighetti, Maddalena Loredana, additional, Mangione, Catello, additional, Lione, Domenico, additional, Casasco, Paola, additional, Nante, Giovanni, additional, Tosetto, Alberto, additional, Oriana, Vincenzo, additional, and Liberato, Nicola Lucio, additional

Published
2023
Full Text
View/download PDF

8. VENOUS THROMBOEMBOLISM SECONDARY TO HOSPITALIZATION FOR COVID-19 DISEASE: PATIENT MANAGEMENT AND LONG-TERM OUTCOMES

Author

Ageno, Walter, primary, Antonucci, Emilia, additional, Poli, Daniela, additional, Bucherini, Eugenio, additional, Chistolini, Antonio, additional, Fregoni, Vittorio, additional, Lerede, Teresa, additional, Pancani, Roberta, additional, Pedrini, Simona, additional, Pieralli, Filippo, additional, Pignatelli, Pasquale, additional, Pizzini, Attilia Maria, additional, Podda, Gian Marco, additional, Potere, Nicola, additional, Sarti, Luca, additional, Testa, Sophie, additional, Visonà, Adriana, additional, and Palareti, Gualtiero, additional

Published
2023
Full Text
View/download PDF

9. Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago

Author

Palareti, Gualtiero, Antonucci, Emilia, Migliaccio, Ludovica, Erba, Nicoletta, Marongiu, Francesco, Pengo, Vittorio, Poli, Daniela, Testa, Sophie, Tosetto, Alberto, Tripodi, Armando, Moia, Marco, Testa, Sophie, Paoletti, Oriana, Guazzaloca, Giuliana, Poli, Daniela, Marcucci, Rossella, Pengo, Vittorio, Falanga, Anna, Lerede, Teresa, Piana, Antonietta, Cibecchini, Francesco, Martini, Giuliana, Ruocco, Lucia, Pedrini, Simona, Masciocco, Lucilla, Saracino, Pasquale, Benvenuto, Angelo, Vasselli, Claudio, Bucherini, Eugenio, Toma, Andrea, Barbera, Pietro, Insana, Antonio, Paparo, Carmelo, Rupoli, Serena, Malcangi, Giuseppe, Sangiorgio, Rossella, Zighetti, Maddalena Loredana, Mangione, Catello, Agostinelli, Enrica, Ageno, Walter, Oriana, Vincenzo, Liberato, Nicola Lucio, Casasco, Paola, Tosetto, Alberto, and On behalf of the centers participating in the FCSA-START-Register (The ISCOAT 2016 study: Italian Study on Complications of Oral Anticoagulant Therapy-2016)

Published
2017
Full Text
View/download PDF

10. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria phenotype in patients with splanchnic vein thrombosis

Author

Ageno, Walter, Dentali, Francesco, De Stefano, Valerio, Barco, Stefano, Lerede, Teresa, Bazzan, Mario, Piana, Antonietta, Santoro, Rita, Duce, Rita, Poli, Daniela, Martinelli, Ida, Siragusa, Sergio, Barillari, Giovanni, Cattaneo, Marco, Vidili, Gianpaolo, Carpenedo, Monica, Rancan, Elena, Giaretta, Ilaria, and Tosetto, Alberto

Published
2014
Full Text
View/download PDF

13. Long‐term outcomes of patients with cerebral vein thrombosis: a multicenter study

Author

DENTALI, F., POLI, D., SCODITTI, U., MINNO, M. N. D. DI, STEFANO, V.D., SIRAGUSA, S., KOSTAL, M., PALARETI, G., SARTORI, M.T., GRANDONE, E., VEDOVATI, M.C., AGENO, W., Falanga, Anna, Lerede, Teresa, Bianchi, Marina, Testa, Sophie, Witt, Dan, McCool, Katie, Bucherini, Eugenio, Grifoni, Elisa, Coalizzo, Daniela, Benedetti, Raffaella, Marietta, Marco, Sessa, Maria, Guaschino, Clara, di Minno, Giovanni, Tufano, Antonella, Barbar, Sofia, Malato, Alessandra, Pini, Mario, Castellini, Paola, Barco, Stefano, Barone, Marisa, Paciaroni, Maurizio, Alberti, Andrea, Agnelli, Giancarlo, Giorgi Pierfranceschi, Matteo, Dulicek, Petr, Silingardi, Mauro, Federica, Landini, Ghirarduzzi, Angelo, Tiraferri, Eros, di Lazzaro, Vincenzo, Rossi, Elena, Ciminello, Angela, Pasca, Samantha, Barillari, Giovanni, Rezoagli, Emanuele, Galli, Matteo, Squizzato, Alessandro, and Tosetto, Alberto

Published
2012
Full Text
View/download PDF

14. Treatment and long-term clinical outcomes of incidental pulmonary embolism in patients with cancer: An international prospective cohort study

Author

Kraaijpoel, Noémie, Bleker, Suzanne M., Meyer, Guy, Mahé, Isabelle, Muñoz, Andrés, Bertoletti, Laurent, Bartels-Rutten, Annemarieke, Beyer-Westendorf, Jan, Porreca, Ettore, Boulon, Carine, van Es, Nick, Iosub, Diana I., Couturaud, Francis, Biosca, Mercedes, Lerede, Teresa, Lacroix, Philippe, Maraveyas, Anthony, Aggarwal, Anita, Girard, Philippe, Büller, Harry R., di Nisio, Marcello, Accassat, S., Aquilant, S., Assaf, J. D., Baars, J., Beenen, L. M., Bergmann, J. F., Bozas, G., Caliandro, R., Carrier, M., Confrere, E., Constans, J., Désormais, I., Dublanchet, N., Endig, S., Falanga, A., Falvo, N., Ferrer Pérez, Al, García Escobar, I., Gonzàlez Santiago, S., Grange, C., Helfer, H., Kleinjan, A., Lalezari, F., de Magalhaes, E., Marten, S., Martinez del Prado, P., Otten, H. M., Paleiron, N., Pérez Ramírez, S., ACS - Pulmonary hypertension & thrombosis, Vascular Medicine, and ARD - Amsterdam Reproduction and Development

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Incidence (epidemiology), Cancer, 030204 cardiovascular system & hematology, medicine.disease, Pulmonary embolism, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Internal medicine, medicine, Cumulative incidence, Clinical significance, Lung cancer, Prospective cohort study, business, Cohort study
Abstract

PURPOSE Pulmonary embolism is incidentally diagnosed in up to 5% of patients with cancer on routine imaging scans. The clinical relevance and optimal therapy for incidental pulmonary embolism, particularly distal clots, is unclear. The aim of the current study was to assess current treatment strategies and the long-term clinical outcomes of incidentally detected pulmonary embolism in patients with cancer. PATIENTS AND METHODS We conducted an international, prospective, observational cohort study between October 22, 2012, and December 31, 2017. Unselected adults with active cancer and a recent diagnosis of incidental pulmonary embolism were eligible. Outcomes were recurrent venous thromboembolism, major bleeding, and all-cause mortality during 12 months of follow-up. Outcome events were centrally adjudicated. RESULTS A total of 695 patients were included. Mean age was 66 years and 58% of patients were male. Most frequent cancer types were colorectal (21%) and lung cancer (15%). Anticoagulant therapy was initiated in 675 patients (97%), of whom 600 (89%) were treated with low-molecular-weight heparin. Recurrent venous thromboembolism occurred in 41 patients (12-month cumulative incidence, 6.0%; 95% CI, 4.4% to 8.1%), major bleeding in 39 patients (12-month cumulative incidence, 5.7%; 95% CI, 4.1% to 7.7%), and 283 patients died (12-month cumulative incidence, 43%; 95% CI, 39% to 46%). The 12-month incidence of recurrent venous thromboembolism was 6.4% in those with subsegmental pulmonary embolism compared with 6.0% in those with more proximal pulmonary embolism (subdistribution hazard ratio, 1.1; 95% CI, 0.37 to 2.9; P = .93). CONCLUSION In patients with cancer with incidental pulmonary embolism, risk of recurrent venous thromboembolism is significant despite anticoagulant treatment. Patients with subsegmental pulmonary embolism seemed to have a risk of recurrent venous thromboembolism comparable to that of patients with more proximal clots.

Published
2019
Full Text
View/download PDF

15. Thrombophilia testing in the real-world clinical setting of thrombosis centres taking part in the Italian Start 2-Register

Author

Legnani, Cristina, Palareti, Gualtiero, Antonucci, Emilia, Poli, Daniela, Cosmi, Benilde, Falanga, Anna, Mastroiacovo, Daniela, Testa, Sophie, Paoletti, Oriana, Morandini, Rossella, Marcucci, Rossella, Maggini, Niccolò, Guazzaloca, Giuliana, Lerede, Teresa, Barcella, Luca, Bucherini, Eugenio, Chiarugi, Paolo, Grandone, Elvira, Colaizzo, Donatella, Pengo, Vittorio, Pignatelli, Pasquale, Pastori, Daniele, Piana, Antonietta, Cibecchini, Francesco, Martini, Giuliana, Bradamante, Salvatore, Masciocco, Lucilla, Paparo, Carmelo, Ageno, Walter, Colombo, Giovanna, Vasselli, Claudio, Toma, Andrea, Visonà, Adriana, Tonello, Diego, Legnani, C., Palareti, G., Antonucci, E., Poli, D., Cosmi, B., Falanga, A., Mastroiacovo, D., and Testa, S.

Subjects
Haemostasis And Thrombosis, Recurrent event, Incidence, anticoagulant, Bleeding, Thrombosis, Venous Thromboembolism, Italy, thrombofilia, Humans, Thrombophilia, VTE, thrombosis, Prospective Studies, Anticoagulant therapy, Factor Xa Inhibitors, Follow-Up Studies
Abstract

Background - Even though it rarely influences venous thromboembolism (VTE) treatment and the fact that it is generally discouraged, thrombophilia testing is still largely prescribed. We assessed: 1) whether/how frequently Italian thrombosis centres requested thrombophilia testing; 2) what results were obtained; and 3) if the results affected treatment and clinical results. Materials and methods - We examined data from 4,826 VTE patients enrolled by 19 clinical centres participating in the START 2-Register. Results - 57.2% of patients were tested. Numbers varied widely among centres (2.9-99.7%). Thrombophilic alterations were recorded in 18.2% of patients and the percentage of positive results was inversely correlated with that of patients tested. Significantly less patients with deep vein thrombosis (DVT) were tested, whereas more were tested when the event was idiopathic, presenting as isolated pulmonary embolism (PE), or in unusual sites. Patients with thrombophilic alterations were younger, more frequently treated with direct oral anticoagulants (DOACs), with lower mortality and less frequently discontinued anticoagulation. DOACs were more frequently prescribed in patients with heterozygous Factor V (FV) Leiden or prothrombin mutations, whereas vitamin K antagonists were preferred in patients with inhibitor deficiencies, combined alterations or antiphospholipid syndrome (APLS). There was no difference in duration of treatment among those with or without alterations, though more APLS patients received an extended treatment course. Bleeding and thrombotic complications occurred with a similar and fairly low incidence in patients with or without thrombophilic alterations. Discussion - Although general testing for thrombophilia in VTE patients is currently discouraged, more than half of the VTE patients included in the START2-Register were tested. However, there were marked differences in practice between Italian thrombosis centres. About 60% of all patients with alterations were treated with DOACs, confirming that DOACs can be a useful option for treatment of thrombophilic VTE patients, with the exclusion of those with APLS. IMTIPRO Sr © SIMTIPRO Srl

Published
2021

16. Safety and Feasibility of a Diagnostic Algorithm Combining Clinical Probability, d-Dimer Testing, and Ultrasonography for Suspected Upper Extremity Deep Venous Thrombosis: A Prospective Management Study

Author

Kleinjan, Ankie, Di Nisio, Marcello, Beyer-Westendorf, Jan, Camporese, Giuseppe, Cosmi, Benilde, Ghirarduzzi, Angelo, Kamphuisen, Pieter W., Otten, Hans-Martin, Porreca, Ettore, Aggarwal, Anita, Brodmann, Marianne, Guglielmi, Maria Domenica, Iotti, Matteo, Kaasjager, Karin, Kamvissi, Virginia, Lerede, Teresa, Marschang, Peter, Meijer, Karina, Palareti, Gualtiero, Rickles, Frederick R., Righini, Marc, Rutjes, Anne W.S., Tonello, Chiara, Verhamme, Peter, Werth, Sebastian, van Wissen, Sanne, and Büller, Harry R.

Published
2014

17. Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register.

Author

Poli, Daniela, Antonucci, Emilia, Ageno, Walter, Prandoni, Paolo, Palareti, Gualtiero, Marcucci, Rossella, the START-COVID Investigators, Colombo, Giovanna, Ambaglio, Chiara, Arpaia, Guido, Barillari, Giovanni, Bitti, Giuseppina, Bucherini, Eugenio, Chistolini, Antonio, Serrao, Alessandra, De Gaudenzi, Egidio, De Micheli, Valeria, Falanga, Anna, Lerede, Teresa, and Barcella, Luca

Abstract

COVID-19 infection causes respiratory pathology with severe interstitial pneumonia and extra-pulmonary complications; in particular, it may predispose to thromboembolic disease. The current guidelines recommend the use of thromboprophylaxis in patients with COVID-19, however, the optimal heparin dosage treatment is not well-established. We conducted a multicentre, Italian, retrospective, observational study on COVID-19 patients admitted to ordinary wards, to describe clinical characteristic of patients at admission, bleeding and thrombotic events occurring during hospital stay. The strategies used for thromboprophylaxis and its role on patient outcome were, also, described. 1091 patients hospitalized were included in the START-COVID-19 Register. During hospital stay, 769 (70.7%) patients were treated with antithrombotic drugs: low molecular weight heparin (the great majority enoxaparin), fondaparinux, or unfractioned heparin. These patients were more frequently affected by comorbidities, such as hypertension, atrial fibrillation, previous thromboembolism, neurological disease, and cancer with respect to patients who did not receive thromboprophylaxis. During hospital stay, 1.2% patients had a major bleeding event. All patients were treated with antithrombotic drugs; 5.4%, had venous thromboembolism [30.5% deep vein thrombosis (DVT), 66.1% pulmonary embolism (PE), and 3.4% patients had DVT + PE]. In our cohort the mortality rate was 18.3%. Heparin use was independently associated with survival in patients aged ≥ 59 years at multivariable analysis. We confirmed the high mortality rate of COVID-19 in hospitalized patients in ordinary wards. Treatment with antithrombotic drugs is significantly associated with a reduction of mortality rates especially in patients older than 59 years. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

18. Clinical Sensitivity to Anthracyclines in PH/BCR+ Acute Lymphoblastic Leukemia

Author

Bassan, Renato, primary, Rohatiner, Ama Z. S., additional, Rambaldi, Alessandro, additional, Lerede, Teresa, additional, Di Bona, Eros, additional, Carter, Maxine, additional, Rossi, Giuseppe, additional, Pogliani, Enrico, additional, Lambertenghi-Deliliers, Giorgio, additional, Fabris, Piero, additional, Porcellini, Adolfo, additional, Lister, T. Andrew, additional, and Barbui, Tiziano, additional

Published
1999
Full Text
View/download PDF

20. Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry

Author

Pastori, Daniele, primary, Antonucci, Emilia, additional, Violi, Francesco, additional, Palareti, Gualtiero, additional, Pignatelli, Pasquale, additional, Testa, Sophie, additional, Paoletti, Oriana, additional, Cosmi, Benilde, additional, Guazzaloca, Giuliana, additional, Migliaccio, Ludovica, additional, Poli, Daniela, additional, Marcucci, Rossella, additional, Maggini, Niccolò, additional, Pengo, Vittorio, additional, Falanga, Anna, additional, Lerede, Teresa, additional, Ruocco, Lucia, additional, Martini, Giuliana, additional, Pedrini, Simona, additional, Bertola, Federica, additional, Masciocco, Lucilla, additional, Saracino, Pasquale, additional, Benvenuto, Angelo, additional, Vasselli, Claudio, additional, Pastori, Daniele, additional, Grandone, Elvira, additional, Colaizzo, Donatella, additional, Marzolo, Marco, additional, Pinelli, Mauro, additional, Ageno, Walter, additional, Colombo, Giovanna, additional, Bucherini, Eugenio, additional, Serra, Domizio, additional, Toma, Andrea, additional, Barbera, Pietro, additional, Paparo, Carmelo, additional, Insana, Antonio, additional, Rupoli, Serena, additional, Malcangi, Giuseppe, additional, Zighetti, Maddalena Loredana, additional, Mangione, Catello, additional, Lione, Domenico, additional, Casasco, Paola, additional, Nante, Giovanni, additional, Tosetto, Alberto, additional, Oriana, Vincenzo, additional, and Liberato, Nicola Lucio, additional

Published
2019
Full Text
View/download PDF

21. Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register.

Author

Antonucci, Emilia, Migliaccio, Ludovica, Abbattista, Maria, Caronna, Antonella, De Marchi, Sergio, Di Giorgio, Angela, Di Giulio, Rosella, Lerede, Teresa, Garzia, Maria Grazia, Martinelli, Ida, Mastroiacovo, Daniela, Marzolo, Marco, Montevecchi, Elisa, Pastori, Daniele, Pignatelli, Pasquale, Poli, Daniela, Ria, Luigi, Santoliquido, Angelo, Testa, Sophie, and Palareti, Gualtiero

Subjects
THROMBOEMBOLISM, VENOUS thrombosis, PATIENT preferences, MEDICAL registries, DECISION making
Abstract

Patients with venous thromboembolism (VTE) should receive a decision on the duration of anticoagulant treatment (AT) that is often not easy to make. Sixteen Italian clinical centers included patients with recent VTE in the START2-POST-VTE register and reported the decisions taken on duration of AT in each patient and the reasons for them. At the moment of this report, 472 (66.9%) of the 705 patients included in the registry were told to stop AT in 59.3% and to extend it in 40.7% of patients. Anticoagulant treatment lasted ≥3 months in >90% of patients and was extended in patients with proximal deep vein thrombosis because considered at high risk of recurrence or had thrombophilic abnormalities. d -dimer testing, assessment of residual thrombus, and patient preference were also indicated among the criteria influencing the decision. In conclusion, Italian doctors stuck to the minimum 3 months AT after VTE, while the secondary or unprovoked nature of the event was not seen as the prevalent factor influencing AT duration which instead was the result of a complex and multifactorial evaluation of each patient. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

22. Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study

Author

Riva, Nicoletta, primary, Ageno, Walter, additional, Poli, Daniela, additional, Testa, Sophie, additional, Rupoli, Serena, additional, Santoro, Rita, additional, Lerede, Teresa, additional, Piana, Antonietta, additional, Carpenedo, Monica, additional, Nicolini, Alberto, additional, Ferrini, Piera Maria, additional, Martini, Giuliana, additional, Mangione, Catello, additional, Contino, Laura, additional, Bonfanti, Carlo, additional, Gresele, Paolo, additional, and Tosetto, Alberto, additional

Published
2015
Full Text
View/download PDF

23. Safety and Feasibility of a Diagnostic Algorithm Combining Clinical Probability,d-Dimer Testing, and Ultrasonography for Suspected Upper Extremity Deep Venous Thrombosis

Author

Kleinjan, Ankie, primary, Di Nisio, Marcello, additional, Beyer-Westendorf, Jan, additional, Camporese, Giuseppe, additional, Cosmi, Benilde, additional, Ghirarduzzi, Angelo, additional, Kamphuisen, Pieter W., additional, Otten, Hans-Martin, additional, Porreca, Ettore, additional, Aggarwal, Anita, additional, Brodmann, Marianne, additional, Guglielmi, Maria Domenica, additional, Iotti, Matteo, additional, Kaasjager, Karin, additional, Kamvissi, Virginia, additional, Lerede, Teresa, additional, Marschang, Peter, additional, Meijer, Karina, additional, Palareti, Gualtiero, additional, Rickles, Frederick R., additional, Righini, Marc, additional, Rutjes, Anne W.S., additional, Tonello, Chiara, additional, Verhamme, Peter, additional, Werth, Sebastian, additional, van Wissen, Sanne, additional, and Büller, Harry R., additional

Published
2014
Full Text
View/download PDF

24. Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study

Author

Dentali, F, Poli, D, Scoditti, U, Di Minno, M, De Stefano, V, Stefano, V, Siragusa, S, Kostal, M, Palareti, G, Sartori, M, Grandone, E, Vedovati, M, Ageno, W, Falanga, A, Lerede, T, Bianchi, M, Testa, S, Witt, D, Mccool, K, Bucherini, E, Grifoni, E, Coalizzo, D, Benedetti, R, Marietta, M, Sessa, M, Guaschino, C, di Minno, G, Tufano, A, Barbar, S, Malato, A, Pini, M, Castellini, P, Barco, S, Barone, M, Paciaroni, M, Alberti, A, Agnelli, G, Giorgi Pierfranceschi, M, Dulicek, P, Silingardi, M, Federica, L, Ghirarduzzi, A, Tiraferri, E, di Lazzaro, V, Rossi, E, Ciminello, A, Pasca, S, Barillari, G, Rezoagli, E, Galli, M, Squizzato, A, Tosetto, A, Di Minno, M N D, Stefano, V D, Sartori, M T, Vedovati, M C, Falanga, Anna, Lerede, Teresa, Bianchi, Marina, Testa, Sophie, Witt, Dan, McCool, Katie, Bucherini, Eugenio, Grifoni, Elisa, Coalizzo, Daniela, Benedetti, Raffaella, Marietta, Marco, Sessa, Maria, Guaschino, Clara, di Minno, Giovanni, Tufano, Antonella, Barbar, Sofia, Malato, Alessandra, Pini, Mario, Castellini, Paola, Barco, Stefano, Barone, Marisa, Paciaroni, Maurizio, Alberti, Andrea, Agnelli, Giancarlo, Giorgi Pierfranceschi, Matteo, Dulicek, Petr, Silingardi, Mauro, Federica, Landini, Ghirarduzzi, Angelo, Tiraferri, Eros, di Lazzaro, Vincenzo, Rossi, Elena, Ciminello, Angela, Pasca, Samantha, Barillari, Giovanni, Rezoagli, Emanuele, Galli, Matteo, Squizzato, Alessandro, Tosetto, Alberto, Dentali, F, Poli, D, Scoditti, U, Di Minno, M, De Stefano, V, Stefano, V, Siragusa, S, Kostal, M, Palareti, G, Sartori, M, Grandone, E, Vedovati, M, Ageno, W, Falanga, A, Lerede, T, Bianchi, M, Testa, S, Witt, D, Mccool, K, Bucherini, E, Grifoni, E, Coalizzo, D, Benedetti, R, Marietta, M, Sessa, M, Guaschino, C, di Minno, G, Tufano, A, Barbar, S, Malato, A, Pini, M, Castellini, P, Barco, S, Barone, M, Paciaroni, M, Alberti, A, Agnelli, G, Giorgi Pierfranceschi, M, Dulicek, P, Silingardi, M, Federica, L, Ghirarduzzi, A, Tiraferri, E, di Lazzaro, V, Rossi, E, Ciminello, A, Pasca, S, Barillari, G, Rezoagli, E, Galli, M, Squizzato, A, Tosetto, A, Di Minno, M N D, Stefano, V D, Sartori, M T, Vedovati, M C, Falanga, Anna, Lerede, Teresa, Bianchi, Marina, Testa, Sophie, Witt, Dan, McCool, Katie, Bucherini, Eugenio, Grifoni, Elisa, Coalizzo, Daniela, Benedetti, Raffaella, Marietta, Marco, Sessa, Maria, Guaschino, Clara, di Minno, Giovanni, Tufano, Antonella, Barbar, Sofia, Malato, Alessandra, Pini, Mario, Castellini, Paola, Barco, Stefano, Barone, Marisa, Paciaroni, Maurizio, Alberti, Andrea, Agnelli, Giancarlo, Giorgi Pierfranceschi, Matteo, Dulicek, Petr, Silingardi, Mauro, Federica, Landini, Ghirarduzzi, Angelo, Tiraferri, Eros, di Lazzaro, Vincenzo, Rossi, Elena, Ciminello, Angela, Pasca, Samantha, Barillari, Giovanni, Rezoagli, Emanuele, Galli, Matteo, Squizzato, Alessandro, and Tosetto, Alberto

Abstract

Background: Little information is available on the long-term clinical outcome of cerebral vein thrombosis (CVT). Objectives and methods: In an international, retrospective cohort study, we assessed the long-term rates of mortality, residual disability and recurrent venous thromboembolism (VTE) in a cohort of patients with a first CVT episode. Results: Seven hundred and six patients (73.7% females) with CVT were included. Patients were followed for a total of 3171 patient-years. Median follow-up was 40months (range 6, 297months). At the end of follow-up, 20 patients had died (2.8%). The outcome was generally good: 89.1% of patients had a complete recovery (modified Rankin Score [mRS] 0-1) and 3.8% had a partial recovery and were independent (mRS 2). Eighty-four per cent of patients were treated with oral anticoagulants and the mean treatment duration was 12months. CVT recurred in 31 patients (4.4%), and 46 patients (6.5%) had a VTE in a different site, for an overall incidence of recurrence of 23.6 events per 1000 patient-years (95% confidence Interval [CI] 17.8, 28.7) and of 35.1 events/1000 patient-years (95% CI, 27.7, 44.4) after anticoagulant therapy withdrawal. A previous VTE was the only significant predictor of recurrence at multivariate analysis (hazard ratio [HR] 2.70; 95% CI 1.25, 5.83). Conclusions: The long-term risk of mortality and recurrent VTE appears to be low in patients who survived the acute phase of CVT. A previous VTE history independently predicts recurrent events.

Published
2012

26. Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups

Author

Bassan, Renato, primary, Chiodini, Barbara, additional, Lerede, Teresa, additional, Giussani, Ursula, additional, Oldani, Elena, additional, Buelli, Maurizio, additional, Rossi, Andrea, additional, Viero, Piera, additional, Rambaldi, Alessandro, additional, and Barbui, Tiziano, additional

Published
2002
Full Text
View/download PDF

27. Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups

Author

Bassan, Renato, primary, Pogliani, Enrico, additional, Casula, Paolo, additional, Rossi, Giuseppe, additional, Fabris, Pietro, additional, Morandi, Sergio, additional, Lambertenghi-Deliliers, Giorgio, additional, Vespignani, Michele, additional, Lerede, Teresa, additional, Rambaldi, Alessandro, additional, Borleri, Gianmaria, additional, Spedini, Pierangelo, additional, Cortelezzi, Agostino, additional, Izzi, Teodosio, additional, Coser, Paolo, additional, Broccia, Giorgio, additional, Corneo, Gianmarco, additional, and Barbui, Tiziano, additional

Published
2001
Full Text
View/download PDF

28. Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR–ABL rearrangements in B-precursor adult acute lymphoblastic leukemia

Author

Bassan, Renato, primary, Rohatiner, Ama ZS, additional, Lerede, Teresa, additional, Di Bona, Eros, additional, Rambaldi, Alessandro, additional, Pogliani, Enrico, additional, Rossi, Giuseppe, additional, Fabris, Pietro, additional, Morandi, Sergio, additional, Casula, Paolo, additional, Carter, Maxine, additional, Lambertenghi-Deliliers, Giorgio, additional, Lister, T Andrew, additional, and Barbui, Tiziano, additional

Published
2000
Full Text
View/download PDF

29. Safety and Feasibility of a Diagnostic Algorithm Combining Clinical Probability, D-Dimer Testing, and Ultrasonography for Suspected Upper Extremity Deep Venous Thrombosis.

Author

Kleinjan, Ankie, Di Nisio, Marcello, Beyer-Westendorf, Jan, Camporese, Giuseppe, Cosmi, Benilde, Ghirarduzzi, Angelo, Kamphuisen, Pieter W., Otten, Hans-Martin, Porreca, Ettore, Aggarwal, Anita, Brodmann, Marianne, Guglielmi, Maria Domenica, Iotti, Matteo, Kaasjager, Karin, Kamvissi, Virginia, Lerede, Teresa, Marschang, Peter, Meijer, Karina, Palareti, Gualtiero, and Rickles, Frederick R.

Subjects
THROMBOSIS, ULTRASONIC imaging, ALGORITHMS, DIAGNOSIS, HOSPITALS
Abstract

Background: Although well-established for suspected lower limb deep venous thrombosis, an algorithm combining a clinical decision score, D-dimer testing, and ultrasonography has not been evaluated for suspected upper extremity deep venous thrombosis (UEDVT). Objective: To assess the safety and feasibility of a new diagnostic algorithm in patients with clinically suspected UEDVT. Design: Diagnostic management study. (ClinicalTrials.gov: NCT01324037) Setting: 16 hospitals in Europe and the United States. Patients: 406 inpatients and outpatients with suspected UEDVT. Measurements: The algorithm consisted of the sequential application of a clinical decision score, Ddimer testing, and ultrasonography. Patients were first categorized as likely or unlikely to have UEDVT; in those with an unlikely score and normal Ddimer levels, UEDVT was excluded. All other patients had (repeated) compression ultrasonography. The primary outcome was the 3-month incidence of symptomatic UEDVT and pulmonary embolism in patients with a normal diagnostic work-up. Results: The algorithm was feasible and completed in 390 of the 406 patients (96%). In 87 patients (21%), an unlikely score combined with normal Ddimer levels excluded UEDVT. Superficial venous thrombosis and UEDVT were diagnosed in 54 (13%) and 103 (25%) patients, respectively. All 249 patients with a normal diagnostic work-up, including those with protocol violations (n = 16), were followed for 3 months. One patient developed UEDVT during follow-up, for an overall failure rate of 0.4% (95% CI, 0.0% to 2.2%). Limitations: This study was not powered to show the safety of the substrategies. DDimer testing was done locally. Conclusion: The combination of a clinical decision score, Ddimer testing, and ultrasonography can safely and effectively exclude UEDVT. If confirmed by other studies, this algorithm has potential as a standard approach to suspected UEDVT. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

30. Granulocyte colony-Stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: Effects, role of patient pretreatment characteristics, and costs

Author

Bassan, Renato, primary, Lerede, Teresa, additional, Bona, Eros Di, additional, Rossi, Giuseppe, additional, Pogliani, Enrico, additional, Rambaldi, Alessandro, additional, Buelli, Maurizio, additional, Viero, Piera, additional, Rodeghiero, Francesco, additional, Izzi, Teodosio, additional, Corneo, Gianmarco, additional, and Barbui, Tiziano, additional

Published
1997
Full Text
View/download PDF

31. Age-Adapted Moderate-Dose Induction and Flexible Outpatient Postremission Therapy for Elderly Patients with Acute Lymphoblastic Leukemia

Author

Bassan, Renato, primary, Bona, Eros Di, additional, Lerede, Teresa, additional, Pogliani, Enrico, additional, Rossi, Giuseppe, additional, D'emilio, Anna, additional, Buelli, Maurizio, additional, Rambaldi, Alessandro, additional, Viero, Piera, additional, Rodeghiero, Francesco, additional, and Barbui, Tiziano, additional

Published
1996
Full Text
View/download PDF

33. Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia.

Author

Bassan R, Lerede T, Borleri G, Chiodini B, Rossi A, Buelli M, Rambaldi A, Viero P, and Barbui T

Subjects
Acute Disease, Adult, Antibiotics, Antineoplastic administration & dosage, Antineoplastic Combined Chemotherapy Protocols toxicity, Cyclosporine administration & dosage, Cytarabine administration & dosage, Dose-Response Relationship, Drug, Drug Resistance, Multiple, Female, Granulocyte Colony-Stimulating Factor administration & dosage, Humans, Idarubicin administration & dosage, Male, Maximum Tolerated Dose, Middle Aged, Salvage Therapy, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Leukemia drug therapy
Abstract

Background and Objectives: Patients with refractory acute myeloid or lymphoid leukemia (AML, ALL) were treated with a high-dose regimen comprising idarubicin (IDR) plus short-course cyclosporin A (CsA) as multidrug resistance type-1 (MDR1) blocking agent. The principal aim was to define the maximum tolerated dose (MTD) of IDR, which is reported to be a less MDR1-sensitive anthracycline. The short CsA infusion was patterned after the results of a previous in vitro study., Design and Methods: This was a phase I trial, in which eligible patients received high-dose cytarabine (HDAC) 3 g/m(2)/bd on days 1, 2 and 8, 9, and IDR 12.5-20 mg/m(2)/d on days 3 and 10, with increments of 2.5 mg/m(2)/d from the baseline per treatment group. Intravenous CsA infusion started 4 hours before IDR and lasted 12 hours. Recombinant granulocyte colony-stimulating factor (G-CSF) was added from day 11. IDR MTD was evaluated through analysis of regimen-related toxicity (RRT)., Results: Eighteen patients were treated (16 AML, 2 ALL; MDR1+: 8/8 studied). Overall response rate was 61%. Toxicity was severe but manageable up to an IDR dose of 17.5 mg/m(2)/d, while grade 4 RRT developed with IDR 20 mg/m(2)/d. High-grade toxicity, not strictly regimen-related, was sometimes observed at lower IDR concentrations in patients with unresolved complications from prior extensive treatments. In keeping, the complete response (CR) rate was 92% (11/12) for patients with an ECOG performance score <2 compared to 0% (0/6) in the others (p=0.000). Apart from that, induction of markedly hypocellular, leukemia-free bone marrow on day 11 was associated with achievement of CR (13 evaluable: CR 8/10 vs 0/3, p=0.035)., Interpretation and Conclusions: IDR at 17.5 mg/m(2)/d (x2) can be associated with short-course CsA and HDAC for the management of refractory acute leukemias. While this regimen could deserve testing in a larger phase II trial, to document activity in MDR1+ disease, it remains important to select the most suitable patients in order to avoid the occurrence of life-threatening cumulative toxicity.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results